MAR 15, 2018 06:23 PM PDT

CasRx - A Genetic Editor That Repairs RNA Errors

WRITTEN BY: Carmen Leitch

Genetic defects cause many different kinds of diseases, and researchers have looked for ways to correct those errors for many years. Several years ago, the CRISPR/Cas9 editor sparked a revolution in molecular biology; it was developed as an incredibly easy and efficient way to edit the genome of any species of interest, and scientists have been tweaking and improving it ever since. These genetic scissors have now been adapted further by scientists at Salk Institute. They took the technology beyond the genome and into an intermediary molecule called RNA. The cell makes DNA into RNA and then finally, makes proteins from that. Many diseases arise due to RNA problems, and this work aims to fix them.

The Salk researchers have also tested their technology by applying it to a patient. Incredibly, they have been able to repair RNA in a person with dementia, and now the patient’s protein levels have been restored to normal. The technique has been called CasRx and has been reported in Cell. This research will surely lead to even more innovation in gene therapy.
 
"Bioengineers are like nature's detectives, searching for clues in patterns of DNA to help solve the mysteries of genetic diseases," said senior author Patrick Hsu, a Helmsley-Salk Fellow. "CRISPR has revolutionized genome engineering, and we wanted to expand the toolbox from DNA to RNA."

CRISPR comes from a bacterial immune system that can dice up invading DNA. In this work, the scientists looked for other kinds of enzymes other than Cas, enzymes that could target RNA, to address errors in it (instead of DNA as in the CRISPR/Cas9 system). RNA has to be transcribed at the proper levels and spliced in the right way to create healthy proteins for cells, but errors in RNA splicing can lead to myriad diseases including cystic fibrosis and frontotemporal dementia (FTD). Targeting those erroneously spliced RNAs could be a boon to patients.

"We began the project with the hypothesis that different CRISPR systems may have been specialized throughout an evolutionary arms race between bacteria and their viruses, potentially giving them the ability to target viral RNA," explained the first author of the work, Salk Research Associate Silvana Konermann, an HHMI Hannah Gray Fellow.

CasRx (magenta) targeting RNA in the nucleus of human cells (gray). / Credit: Salk Institute

Using a computational program they created to interrogate bacterial DNA, the investigators scoured databases for CRISPR signatures. They are characterized by repeating patterns of genetic sequences. Their work revealed a family of CRISPR enzymes that can target RNA; they called it Cas13d.

Just like enzymes from the Cas9 family, Cas13d enzymes that come from different kinds of bacteria have different activity levels. The team looked for the ones that would be ideal for use in human cells and found that an enzyme from a gut bacterium, Ruminococcus flavefaciens XPD3002, would be best.

"Once we engineered CasRx to work well in human cells, we really wanted to put it through its paces," noted Konermann.

The researchers used their new enzyme to fix a problem in disease. The ratio of a protein called tau is imbalanced in neurons in the neurodegenerative disorder FTD. An RNA sequence that codes for tau was targeted, because it appears at excessive levels in the disorder. CasRx was packaged with a virus, and stem cells from an FTD patient were exposed to that. Those cells grew into neurons, and a balance was restored in the patient; CasRx was 80 percent effective at recalibrating the tau protein levels.

Because CasRx is small, it may be easy to deliver to a patient. It also did not exhibit off-target effects, an amazing feat considering how effective it was. The Salk team wants to continue to explore how this system can be used.

"Nature is full of so many secrets," added Hsu. "It's really a rich, untapped resource for inventing new technologies."

 

Sources: AAAS/Eurekalert! via Salk Institute, Cell

About the Author
  • Experienced research scientist and technical expert with authorships on 28 peer-reviewed publications, traveler to over 60 countries, published photographer and internationally-exhibited painter, volunteer trained in disaster-response, CPR and DV counseling.
You May Also Like
JAN 17, 2020
Genetics & Genomics
JAN 17, 2020
Can CRISPR Replace Antibiotics?
Antibiotic-resistant infections claim around 700,000 lives per year, with estimates saying that this number could swell to 10 million by 2050 (Jacobs: 2019...
JAN 17, 2020
Genetics & Genomics
JAN 17, 2020
Understanding How Loose RNA Molecules Help Rejuvenate Skin
This work may help develop new treatments for skin that is aging or damaged by wounds or burns....
JAN 17, 2020
Genetics & Genomics
JAN 17, 2020
An Epigenetic Switch Changes Warrior Ants Into Foragers
Researchers were able to change the behavior of a type of carpenter ant, and now they know the biological basis for the change....
JAN 17, 2020
Drug Discovery & Development
JAN 17, 2020
FDA Approves New Drug for Sickle Cell Disease
Sickle cell disease affects approximately 100,000 Americans. Currently, the only available cure for the disease is a costly bone marrow transplant, putting...
JAN 17, 2020
Microbiology
JAN 17, 2020
Flesh-Eating Infection Turns Deadly When Two Microbes Are to Blame
Some illnesses can happen because a person is infected with more than one microbial pathogen, and these pathogens can interact....
JAN 17, 2020
Genetics & Genomics
JAN 17, 2020
A New Type of Muscle Cell That Could be a Target for Gene Therapy is ID'ed
Muscles have a supply of restorative stem cells called satellite cells, and now they have identified a new type....
Loading Comments...